Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2022-04-25 Regulatory Filings
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
License partner of Xlife Sciences announces successful completion of phase 1 of in-vivo trial for ATROSIMAB out-licensing of the compound intended
Regulatory Filings Classification · 1% confidence The document is explicitly labeled as an "Ad-hoc" announcement released pursuant to Art. 53 LR (Listing Rules), which is characteristic of immediate, material information disclosure required by stock exchanges. The content details a successful R&D milestone (completion of Phase 1 trial for ATROSIMAB) and future intentions (out-licensing). This type of immediate, material corporate news that doesn't fit neatly into standard periodic reports (like 10-K or IR) or specific corporate actions (like DIV or CAP) is best classified as a general Regulatory Filing or Announcement. Since 'Regulatory Filings (RNS)' is defined as the fallback for miscellaneous filings that do not neatly fit elsewhere, and this is a standard ad-hoc regulatory disclosure, RNS is the most appropriate code. The document length (4230 chars) is not short enough to trigger the RPA rule based on the 'Menu vs Meal' criteria, as it contains substantive news, not just a pointer to another document.
2022-04-25 English
Xlife Sciences: Date of publication Annual Report 2022
Report Publication Announcement Classification · 1% confidence The document is an 'Ad-hoc' announcement dated April 21, 2022. The primary content states that Xlife Sciences AG will publish its 'annual report 2021 newly on 29 April 2022' due to an auditor change. It then lists a 'Financial calendar' which includes the 'Annual Report 2022' scheduled for April 29, 2022. Since the document itself is not the Annual Report (10-K) but rather an announcement about the *date of publication* of the Annual Report, it fits the definition of a Report Publication Announcement (RPA). The document length (3270 chars) is short, supporting the 'MENU VS MEAL' rule.
2022-04-21 English
Xlife Sciences AG: Xlife Sciences' shares begin trading on SIX Swiss Exchange
Regulatory Filings Classification · 1% confidence The document is an 'Ad-hoc' announcement dated February 11, 2022, disclosing that Xlife Sciences AG's shares began trading on the SIX Swiss Exchange, including details about the ticker symbol, reference price, and market capitalization. This announcement relates to a significant corporate event concerning the listing and trading of securities, which falls under capital structure changes or major corporate actions. While it mentions future reports (Annual Report, AGM), the core content is the commencement of trading on a new exchange, which is a form of capital/financing update or a general regulatory disclosure. Given the options, 'Capital/Financing Update' (CAP) is the most fitting category as it details the listing event and capital structure (share count, market cap). It is not a formal report (10-K, IR) but an announcement of a corporate action related to its listing status.
2022-02-11 English
Xlife Sciences AG: Xlife Sciences publishes prospectus for listing on SIX Swiss Exchange
Regulatory Filings Classification · 1% confidence The document is an 'Ad-hoc' announcement dated February 8, 2022, titled 'Xlife Sciences publishes prospectus for listing on SIX Swiss Exchange'. It explicitly states that the company 'today has published the prospectus for its intended listing on the “Sparks” segment of SIX Swiss Exchange.' It also mentions the publication of 'audited interim financial statements as of 30 September 2021' alongside the prospectus. Since the core subject is the announcement of the publication of a prospectus related to a stock exchange listing (a significant corporate action) and the release of associated financial statements, this is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP). However, the primary action described is the publication of the prospectus for the listing, which is a regulatory disclosure event. Given the context of a prospectus publication for a listing, which often involves capital structure changes and regulatory compliance, 'CAP' (Capital/Financing Update) is a strong candidate, but 'RNS' (Regulatory Filings) is the most appropriate general category for official, ad-hoc regulatory disclosures that aren't strictly earnings or management changes. Since the document is announcing the availability of a prospectus for a listing, which is a major corporate event often filed under general regulatory news, RNS is the safest fit, although CAP is also plausible. Given the nature of the announcement (publishing a prospectus for a listing), it strongly relates to capital market activity. I will lean towards RNS as it is an ad-hoc disclosure of a regulatory document (prospectus).
2022-02-08 English
Listing and first trading day on the 'Sparks' segment of SIX Swiss Exchange expected for February 11, 2022
Regulatory Filings Classification · 1% confidence The document is a press release dated February 1, 2022, announcing the intended listing and first trading day of Xlife Sciences AG shares on the 'Sparks' segment of the SIX Swiss Exchange for February 11, 2022. It also mentions the revocation of trading on the Munich Stock Exchange. This announcement relates to a significant change in the company's capital structure and listing status, specifically an Initial Public Offering (IPO) related event. While it discusses a future listing, it is not a formal prospectus or a standard regulatory filing like a 10-K or IR. It is an announcement concerning capital market activity. The closest fit among the provided codes is 'CAP' (Capital/Financing Update), as an IPO/listing is a primary financing activity. It is not a general regulatory filing (RNS) because it fits the specific 'CAP' definition better, nor is it a formal share issue announcement (SHA) which usually relates to subsequent capital changes or buybacks, although an IPO is related to share issuance. Given the context of listing and market entry, CAP is the most appropriate classification for this financing event announcement.
2022-02-01 English
Xlife Sciences raises CHF 5.0 million through capital increase
Capital/Financing Update Classification · 1% confidence The document is an 'Ad-hoc' announcement dated January 26, 2022, explicitly stating that 'Xlife Sciences raises CHF 5.0 million through capital increase'. It details the issuance of new shares via a private placement and the resulting change in share capital. This content directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition for Capital/Financing Update (Code: CAP). Although it is a press release format, the core subject matter is the capital action itself, not just the announcement of a report.
2022-01-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.